RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
GlobalData on MSN2d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The ...
Pharmabiz2d
BioMarin Pharma’s phase 3 PEGASUS trial evaluating Palynziq in adolescents with phenylketonuria meets primary efficacy endpoint
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
Zacks Investment Research on MSN3d
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to Buy at StockNews.com
StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...
The Pharma Letter1d
Positive pivotal data for Palynziq in adolescents
US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...
Medindia2d
BioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...